Please assess the completion status of the following clinical trial:

Trial Title: Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or post-menopausal females aged 21-80 years.~2. Hypertensive patients (BP \>135/85) will be eligible to participate.~3. Patients on current anti-hypertensive therapy that does not include beta blockade should have BP \>135/85.~4. Patients on anti-hypertensive therapy including beta blockade will have their beta blockers discontinued gradually over 2 weeks before enrolment.~5. Concomitant therapy: Patients will be allowed to be on comcomitant therapy with aspirin, statins, thiazide diuretics, calcium antagonists (for treatment of hypertension), clonidine, vasodilators, or angiotensin antagonists. Patients will be on stable medical therapy for at least 2 months before recruitment. Patients with previous treatment with beta adrenergic blockers (metoprolol, propranolol, atenolol, and labetalol) will also be eligible to participate, but will be randomized to the study beta blocker.~Exclusion Criteria:~1. Age \< 21 or \>80 years~2. Initiation or change in dose of statin or anti-hypertensive therapy within 2 months before the study~3. Premenopausal females with potential for pregnancy~4. Acute infection in previous 2 weeks~5. History of substance abuse~6. Current neoplasm~7. Chronic renal failure \[creatinine \> 2.5 mg/dL\] or liver failure (Liver enzymes \>2X normal)~8. Acute coronary syndrome, Class IV heart failure, CVA, coronary intervention within 2 months~9. Known aortic stenosis, hypertrophic cardiomyopathy.~10. Inability to give informed consent~11. Inability to return to Emory for follow-up testing

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Nebivolol/ Metoprolol (Type: ACTIVE_COMPARATOR): Subjects were randomized to nebivolol for 3 months. They crossed over to take 3 months of metoprolol succinate. The initial 5 mg daily dose of nebivolol was titrated to 10 mg daily after 2 weeks if their BP remained \>125/80, and subsequently titrated to 20 mg daily after another 2 weeks if the BP remained \>125/80. Similarly, the initial 50 mg daily dose of metoprolol succinate was titrated to 100 mg daily after 2 weeks if BP remained \>125/80, and further increased to 200 mg after 2 weeks if BP remained \>125/80.
- Metoprolol/Nebivolol (Type: ACTIVE_COMPARATOR): Subjects were randomized to metoprolol succinate for 3 months. They crossed over to take 3 months of nebivolol. The initial 5 mg daily dose of nebivolol was titrated to 10 mg daily after 2 weeks if their BP remained \>125/80, and subsequently titrated to 20 mg daily after another 2 weeks if the BP remained \>125/80. Similarly, the initial 50 mg daily dose of metoprolol succinate was titrated to 100 mg daily after 2 weeks if BP remained \>125/80, and further increased to 200 mg after 2 weeks if BP remained \>125/80.

Based on this trial design, predict the completion outcome and termination type (if applicable).